In this context, it is worth pointing out that Shh has been implicated in the pathogenesis of several types of cancer and that anti-Hh strategies are currently used, or are under investigation, for the treatment of many neoplastic diseases, including basal cell carcinoma, acute promyelocytic leukemia, medulloblastoma, small cell lung cancer, pancreatic cancer, intracranial meningioma, recurrent glioblastoma, prostate cancer, renal cell carcinoma, and colon cancer. The gene discussed is SHH; the disease is prostate cancer.